Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
NCT07772882Phase 1Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of arginine in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (2 cohorts). Primary endpoint: Proportion of patients with serious adverse events. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
arginine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT07772882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07772882.